What is the category of COVID-19 patients that require plasma therapy? Is there any category of patients who cannot undertake it, because of other health complications?
People who have moderate to severe illness are the right candidates for treatment through plasma therapy. Medically, I would say people who have pneumonia with type I respiratory failure and acute respiratory distress syndrome (ARDS) are the category of patients for this treatment. Patients with mild illness do not require plasma therapy and the treatment is futile in patients with very critical illness with multi-organ failure. There are no other medical conditions under which a patient cannot get this treatment.
How effective is the therapy?
Obviously, it is not a magic bullet and not 100% effective. It is one of the good treatment options available because as of now we do not have any definitive treatment for COVID-19. Most of the therapies are either experimental or have some effectiveness. This is one of the promising therapies, however, it is not an established treatment. More studies are needed to confirm its effectiveness but small studies have merged from the US- they are series of 5-patient report or 10-patient report.
In one series of 5-patient report, all 5 patients on ventilator have successfully come out of it and in another 10 series patients, they found the virus clearing happened rapidly after giving plasma treatment. Therefore, reports like these coupled with our first successful case where the patient responded well to the treatment indicate that plasma therapy is potentially effective therapy. However, larger studies need to be conducted to really say how effective it is.
How is the procedure conducted?
This story is from the May 2020 edition of Healthcare Radius.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the May 2020 edition of Healthcare Radius.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
Entod opens R&D center in Navi Mumbai
ENTOD Pharmaceuticals inaugurates a new R&D center in Navi Mumbai, focusing on innovative pharmaceutical solutions and global leadership.
DEDICATED ECMO UNITS: A POST-COVID IMPERATIVE
In the post-Covid world, the necessity of dedicated ECMO units have become paramount for managing critical cases efficiently, says the author.
HOPE AMIDST HESITATION?
The Union Finance Minister Nirmala Sitharaman's Budget 2024-25 elicited a mixed response from healthcare sub-segments.
THE WONDERS OF WEARABLES Discover how wearables can offer a new hope to migraine patients in India.
Digital therapeutics (Dtx) is an emerging concept for therapeutic approaches in healthcare system.
ONLINE HEALTHCARE CONSULTATIONS: A TRANSFORMATION UNFOLDING
Discover how online consultations are transforming India’s healthcare landscape with the use of advanced technologies.
DRUG-RESISTANT TUBERCULOSIS: A CHALLENGE IN THE LAST LAP?
India aims to eliminate tuberculosis by 2025, but drug-resistant strains pose a formidable challenge. Explore healthcare leaders’ views and potential solution approaches they offer—in this report.
Meghalaya Cancer Conclave 2024 discusses cancer care in the state
Led by Dr Mazel Ampareen Lyngdoh, conclave focuses on critical cancer care issues.
Woman with atrial septal defect saved at Medica
A middle-aged woman from West Bengal suffering from Atrial Septal Defect ASD) successfully undergoes a complex procedure at Medica Hospital.
Breastfeeding education initiative launched
RISHTA 2024: An initiative by BSV and FOGSI to enhance breastfeeding education in India.
5-kg fibroid removed with minimally invasive myomectomy
Doctors at Sahyadri Hospitals in Pune removed a 5-kg fibroid from a 35-year-old woman using a minimally invasive myomectomy, typically used in cesarean sections.